Veracyte | VCYT - Sales Revenues


Veracyte reported $139.07M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Agenus USD 34.2M 3.97M Dec/2025
Agilent USD 1.8B 63M Dec/2025
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 73.74M 190.29M Mar/2026
Bruker USD 823.4M 153.8M Mar/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Illumina USD 1.09B 70M Mar/2026
Intrexon USD 717K 511K Jun/2024
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Laboratory Of America USD 3.54B 20M Mar/2026
Ligand Pharmaceuticals USD 51.72M 7.94M Mar/2026
Myriad Genetics USD 200.4M 9.4M Mar/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Siemens EUR 19.76B 620M Mar/2026
Sonic Healthcare AUD 5.45B 470M Dec/2025
Thermo Fisher Scientific USD 11.01B 1.2B Mar/2026
Veracyte USD 139.07M 1.53M Mar/2026
Waters USD 1.27B 338M Mar/2026